

**Memo no.:** 2026-009  
**Date:** 22-June-2026  
**Memo to:** Clients  
**Re:** ***Fluoxetine and Metabolite, Serum/Plasma – Change in Methodology***

---

Due to unforeseen circumstances at the performing laboratory, effective immediately, the performing laboratory has implemented a change in methodology for [Fluoxetine and Metabolite, Serum/Plasma](#). The method has been changed from high-performance liquid chromatography with fluorescence detection (HPLC-FLD) to an ultra-performance liquid chromatography with tandem mass spectrometry detection.

Due to expedited implementation of the new method, the lab's LIS build to reflect this change will not be completed until July 14, 2026.

In the interim, samples will be tested using the new method but will be flagged and reported showing the previous reference intervals, which should be ignored.

The lab has added the following report comment to advise of the change:

*“This sample was analyzed with our new LC-MS/MS method. This method has different therapeutic reference range, where both fluoxetine and its metabolite have only one combine range: 388 – 1695 nmol/L”.*

Test	Revised Reference Intervals
<a href="#">Fluoxetine and Metabolite, Serum/Plasma</a>	Fluoxetine: 388 – 1695 nmol/L Norfluoxetine: 388 – 1695 nmol/L

---

If you have further questions, please contact Client Care at 416-422-3000 ext. 300 or [info@iclabs.ca](mailto:info@iclabs.ca)

**Dr. Shashank Tilak, Ph.D., DCC**  
Laboratory Director  
416-422-3000 ext. 221  
[shashtilak@iclabs.ca](mailto:shashtilak@iclabs.ca)